News Related to ErbB2

Related coverage linked through entity extraction aliases.

SONIA Trial Finds No Overall Survival Benefit for First-Line CDK4/6 Inhibitors in Advanced Breast Cancer

Apr 02, 2026

The SONIA trial found no overall survival benefit for first-line CDK4/6 inhibitors versus second-line use in advanced HR+/HER2- breast cancer. Median survival was 47.9 vs 48.1 months, though post hoc analysis suggested benefit in premenopausal patients. First-line treatment was associated with more severe adverse events.

HER2-Positive Gastric Cancer Pipeline Expands with 20+ Therapies in Development

Mar 22, 2026

Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.

Cogent Biosciences Prepares Up to Three FDA Filings for Bezuclastinib Following Pivotal Wins

Mar 15, 2026

Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.